Výsledky vyhledávání - "Jean J L, Tessier"

Supplementary Methods from First-in-Human, Phase I Dose-Escalation Study of the Safety, Pharmacokinetics, and Pharmacodynamics of RO5126766, a First-in-Class Dual MEK/RAF Inhibitor in Patients with Solid Tumors

Autor: Jean-Charles Soria, Valerie Meresse Naegelen, Steve Blotner, Eliezer Shochat, Jean J. L. Tessier, Ruediger Rueger, Zhi-Xin Xu, Ernesto Guarin, Emilie Routier, Federico Rojo, Françoise Kraeber-Bodéré, Saoirse Dolly, Rastilav Bahleda, Joan Albanell, Udai Banerji, Maria Martinez-Garcia

PDF file, 130K.

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::006b8947be1db4b35cb0c1be9eb3d2ac
https://doi.org/10.1158/1078-0432.22451105.v1

Zobrazit plný text záznamu

Data from First-in-Human, Phase I Dose-Escalation Study of the Safety, Pharmacokinetics, and Pharmacodynamics of RO5126766, a First-in-Class Dual MEK/RAF Inhibitor in Patients with Solid Tumors

Purpose: This phase I study assessed the maximum tolerated dose (MTD), dose-limiting toxicities (DLT), safety, pharmacokinetics, pharmacodynamics, and clinical activity of the first-in-class dual MEK/RAF inhibitor, RO5126766.Experimental Design: Init

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::bbca345e19eeb5455a74ad1913cfe943
https://doi.org/10.1158/1078-0432.c.6522101

Zobrazit plný text záznamu

Supplementary Figure 1 from First-in-Human, Phase I Dose-Escalation Study of the Safety, Pharmacokinetics, and Pharmacodynamics of RO5126766, a First-in-Class Dual MEK/RAF Inhibitor in Patients with Solid Tumors

PDF file, 18K, Schematic showing cohort doses evaluated, dose-limiting-toxicities observed and maximum-tolerated-doses per dosing regimen.

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b59472046794d1c2b3578f6cc4e14ad1
https://doi.org/10.1158/1078-0432.22451108.v1

Zobrazit plný text záznamu

Supplementary Table 1 from First-in-Human, Phase I Dose-Escalation Study of the Safety, Pharmacokinetics, and Pharmacodynamics of RO5126766, a First-in-Class Dual MEK/RAF Inhibitor in Patients with Solid Tumors

PDF file, 9K, Summary of pharmacokinetics of RO4987655 in patients following oral administration.

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::088e1989b219d8b25cb6ff3d615e9d0d
https://doi.org/10.1158/1078-0432.22451102.v1

Zobrazit plný text záznamu

The PET-Tracer

Publikováno v: Cancer research. 80(13)

CD8-expressing T cells are the main effector cells in cancer immunotherapy. Treatment-induced changes in intratumoral CD8

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid________::21c72fedb1a7da97d0cbdc9b48404fdb
https://pubmed.ncbi.nlm.nih.gov/32409308

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání